Catalent Pharma Solutions and BASF have entered into a collaboration aimed at providing solutions for bioavailability challenges of new molecular entities with solubility or permeability issues. The companies will combine their expertise to provide a range of services to address pipeline challenges with BCS Class II and IV poorly bioavailable compounds. Services include: feasibility studies across multiple technologies, solid state chemistry, consulting and training, expert formulation services...